Wednesday, May 12, 2010 1:49:06 PM
BOSTON (MarketWatch) -- Shares of Poniard Pharmaceuticals /quotes/comstock/15*!pard/quotes/nls/pard (PARD 1.29, +0.04, +3.20%) moved up 14% to $1.18 Monday afternoon. Poniard said that it plans to release Phase III data from a lung-cancer clinical trial for its chemotherapy agent picoplatin on June 5 at the annual meeting of the American Society of Clinical Oncology.
GLTA
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM